Tumor- and osteoclast-derived NRP2 in prostate cancer bone metastases
Open Access
- 14 May 2021
- journal article
- research article
- Published by Springer Science and Business Media LLC in Bone Research
- Vol. 9 (1), 1-16
- https://doi.org/10.1038/s41413-021-00136-2
Abstract
Understanding the role of neuropilin 2 (NRP2) in prostate cancer cells as well as in the bone microenvironment is pivotal in the development of an effective targeted therapy for the treatment of prostate cancer bone metastasis. We observed a significant upregulation of NRP2 in prostate cancer cells metastasized to bone. Here, we report that targeting NRP2 in cancer cells can enhance taxane-based chemotherapy with a better therapeutic outcome in bone metastasis, implicating NRP2 as a promising therapeutic target. Since, osteoclasts present in the tumor microenvironment express NRP2, we have investigated the potential effect of targeting NRP2 in osteoclasts. Our results revealed NRP2 negatively regulates osteoclast differentiation and function in the presence of prostate cancer cells that promotes mixed bone lesions. Our study further delineated the molecular mechanisms by which NRP2 regulates osteoclast function. Interestingly, depletion of NRP2 in osteoclasts in vivo showed a decrease in the overall prostate tumor burden in the bone. These results therefore indicate that targeting NRP2 in prostate cancer cells as well as in the osteoclastic compartment can be beneficial in the treatment of prostate cancer bone metastasis.Keywords
Funding Information
- rudolf becker foundation for translational prostate cancer research
This publication has 49 references indexed in Scilit:
- Current Understanding of RANK Signaling in Osteoclast Differentiation and MaturationMolecules and Cells, 2017
- NRP2 transcriptionally regulates its downstream effector WDFY1Scientific Reports, 2016
- Neuropilin Functions as an Essential Cell Surface ReceptorOnline Journal of Public Health Informatics, 2015
- The role of osteoclast differentiation and function in skeletal homeostasisThe Journal of Biochemistry, 2015
- Perspectives on Treatment of Metastatic Castration-Resistant Prostate CancerThe Oncologist, 2013
- CXCL10 Promotes Osteolytic Bone Metastasis by Enhancing Cancer Outgrowth and OsteoclastogenesisCancer Research, 2012
- The Involvement of TRP Channels in Bone HomeostasisFrontiers in Endocrinology, 2012
- Bone metastasis in prostate cancer: emerging therapeutic strategiesNature Reviews Clinical Oncology, 2011
- Impact of Comorbidity on Survival of Danish Prostate Cancer Patients, 1995–2006: A Population-Based Cohort StudyUrology, 2008
- Potentiation and inhibition of Ca2+ release‐activated Ca2+ channels by 2‐aminoethyldiphenyl borate (2‐APB) occurs independently of IP3 receptorsJournal Of Physiology-London, 2001